Release no. 18/2011

Copenhagen and Oslo, 12th October, 2011, 2011-10-12 09:00 CEST (GLOBE NEWSWIRE)
--
Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced
today that the U.S. Patent and Trademark Office (USPTO) has granted Affitech
U.S. patent (no. 8,034,905) covering the Company's leading anti-VEGF antibody
drug candidate AT001/r84. The newly granted US patent is the first patent grant
Affitech has received for this compound in a major territory and it
considerably strengthens Affitech's IP position regarding this drug candidate.
The patent is co-owned by Affitech and its collaboration partner Peregrine
Pharmaceuticals.

Commenting on the new patent, Managing Director of Affitech A/S Martin Welschof
said:

“The grant of the patent on AT001/r84 by the USPTO is pleasant news. We hereby
extend our patent portfolio for AT001/r84 to include USA, which is important
for the further development of this antibody drug candidate. The development of
AT001/r84 is progressing well and IBC Generium expects to commence the first
phase 1 clinical trial with the drug candidate before year end 2011.”


About AT001/r84

AT001/r84 is a novel, proprietary therapeutic antibody to vascular endothelial
growth factor (VEGF) being developed by Affitech and IBC Generium as a
potential alternative to bevacizumab (Avastin®) for the treatment of certain
human cancers. The Russian health authorities have identified cancer therapy
based on anti-VEGF antibodies as one of the top priority areas of
pharma-innovation in Russia. Affitech's AT001/r84 has the potential to satisfy
patient needs in this area. The rights to develop and commercialize AT001/r84
outside Russia and the CIS remain with Affitech.





About Affitech

Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company based in Copenhagen, Denmark with R&D facilities in Oslo,
Norway. The company utilizes a range of proprietary antibody technologies for
the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to
cell surface molecules. Affitech co-develops its two lead antibody drug
programs AT001/r84 and AT008/CCR4 with Russian partner IBC Generium. The
Company's initial focus is on rapid and cost effective development by
partnering clinical trials in emerging markets. Further information is
available at www.affitech.com.



Disclaimer
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of the financial condition and operations of Affitech A/S. There are many
factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements and
forecasts. These factors include, among other things, risks associated with
technological development, the risk that research & development will not yield
new products that achieve commercial success, the impact of competition, the
ability to transact viable and profitable commercial deals, the risk of
non-approval of patents not yet granted, and difficulties of obtaining relevant
governmental approvals for new products.


No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided
herein, and no claims shall be made by the recipient of this news release by
virtue of the information contained herein.


.



Contact:

Randi Krogsgaard, Director IR & Corporate Communications

Tel # +45 2320 1001, e-mail: [email protected]

111012_PR_USpatent_UK_Final.pdf